FY2026 EPS Estimates for Amedisys Raised by Leerink Partnrs

Amedisys, Inc. (NASDAQ:AMED) – Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for shares of Amedisys in a report released on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now anticipates that the health services provider will earn $5.06 per share for the year, up from their prior forecast of $4.53. The consensus estimate for Amedisys’ current full-year earnings is $4.43 per share.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $92.50 on Monday. The firm’s 50 day moving average is $89.41 and its two-hundred day moving average is $93.96. The firm has a market capitalization of $3.03 billion, a P/E ratio of 36.71, a PEG ratio of 1.84 and a beta of 0.72. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a 52 week low of $82.15 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $587.67 million for the quarter, compared to analyst estimates of $586.75 million. During the same period last year, the firm posted $0.98 EPS. The business’s revenue was up 5.7% compared to the same quarter last year.

Institutional Trading of Amedisys

Several large investors have recently added to or reduced their stakes in AMED. National Bank of Canada FI grew its stake in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after purchasing an additional 30,213 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Amedisys by 1.3% in the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after purchasing an additional 7,071 shares during the period. Quarry LP bought a new position in Amedisys in the 3rd quarter valued at about $2,569,000. Charles Schwab Investment Management Inc. increased its stake in Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after buying an additional 9,004 shares during the period. Finally, Holocene Advisors LP raised its position in shares of Amedisys by 391.4% during the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock worth $7,628,000 after buying an additional 62,953 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.